# A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Multiple Oral Doses (6 Days) of 100 mg Resmetirom in Subjects With Severe Renal Impairment and in Matched Healthy Control Subjects With Normal Renal Function

> **NCT06397872** · PHASE1 · COMPLETED · sponsor: **Madrigal Pharmaceuticals, Inc.** · enrollment: 28 (actual)

## Conditions studied

- Renal Impairment

## Interventions

- **DRUG:** 100 mg Resmetirom Tablet

## Key facts

- **NCT ID:** NCT06397872
- **Lead sponsor:** Madrigal Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-03-06
- **Primary completion:** 2024-09-16
- **Final completion:** 2024-12-31
- **Target enrollment:** 28 (ACTUAL)
- **Last updated:** 2025-10-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06397872

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06397872, "A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Multiple Oral Doses (6 Days) of 100 mg Resmetirom in Subjects With Severe Renal Impairment and in Matched Healthy Control Subjects With Normal Renal Function". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06397872. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*